Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) Director Jane A. Gross purchased 3,750 shares of the company's stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average price of $4.00 per share, for a total transaction of $15,000.00. Following the completion of the purchase, the director now directly owns 9,750 shares in the company, valued at $39,000. This represents a 62.50 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Atyr PHARMA Stock Performance
Atyr PHARMA stock opened at $4.01 on Tuesday. The firm's 50 day simple moving average is $3.65 and its 200 day simple moving average is $3.09. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $336.61 million, a PE ratio of -4.27 and a beta of 0.98. Atyr PHARMA INC has a 1-year low of $1.42 and a 1-year high of $4.66.
Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. As a group, analysts expect that Atyr PHARMA INC will post -0.91 earnings per share for the current fiscal year.
Analysts Set New Price Targets
ATYR has been the topic of a number of recent research reports. Leerink Partners initiated coverage on shares of Atyr PHARMA in a research note on Tuesday, February 18th. They set an "outperform" rating and a $16.00 price target on the stock. HC Wainwright restated a "buy" rating and set a $35.00 price target on shares of Atyr PHARMA in a research note on Friday. Leerink Partnrs raised shares of Atyr PHARMA to a "strong-buy" rating in a report on Tuesday, February 18th. Finally, Cantor Fitzgerald assumed coverage on shares of Atyr PHARMA in a report on Monday, January 6th. They set an "overweight" rating on the stock. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Atyr PHARMA has an average rating of "Buy" and a consensus target price of $18.60.
Read Our Latest Research Report on Atyr PHARMA
Hedge Funds Weigh In On Atyr PHARMA
Institutional investors have recently made changes to their positions in the stock. Group One Trading LLC bought a new position in shares of Atyr PHARMA in the 4th quarter worth $26,000. Alterna Wealth Management Inc. bought a new position in shares of Atyr PHARMA in the 4th quarter worth $36,000. Victory Capital Management Inc. bought a new position in shares of Atyr PHARMA in the 4th quarter worth $37,000. Raymond James Financial Inc. bought a new position in shares of Atyr PHARMA in the 4th quarter worth $39,000. Finally, XTX Topco Ltd bought a new position in shares of Atyr PHARMA in the 4th quarter worth $40,000. Institutional investors own 61.72% of the company's stock.
About Atyr PHARMA
(
Get Free Report)
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
